Arthritis, Psoriatic News and Research

RSS

Study estimates the quality of care for patients with long-term health conditions

The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.

4 Nov 2022

Study finds an increase in the proportion of adults in England diagnosed with inflammatory arthritis

The proportion of adults in England diagnosed with inflammatory arthritis has increased by at least 40% between 2004 to 2020, new Keele University research has found.

25 Oct 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Researchers in the UK have conducted a large population-based study showing that people with immune-mediated inflammatory diseases (IMIDs) appear to be at an increased risk of serious outcomes from coronavirus disease 2019 (COVID-19).

14 Sep 2021

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK.

24 Aug 2021

Exploring young people’s perspectives on patient-reported outcome measures in inflammatory arthritis

Inflammatory arthritis is the name for a group of diseases that cause joint pain and swelling. This happens because the body's immune system attacks its own tissues and causes inflammation.

23 Jun 2021

People taking anti-inflammatory drug mount a weaker immune response to COVID-19 vaccine

One-quarter of people who take the drug methotrexate for common immune system disorders -- from rheumatoid arthritis to multiple sclerosis -- mount a weaker immune response to a COVID-19 vaccine, a new study shows.

2 Jun 2021

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.

8 Nov 2020

High-resolution TB-PET/CT scanner reveals complete picture of systemic inflammatory arthritis

For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneously across all joints and organ systems, using the high-sensitivity, high-resolution uEXPLORER total-body positron emission tomography/computed tomography (TB-PET/CT) scanner.

13 Jul 2020

Research project moves one step closer to personalized treatment of rheumatic diseases

When a patient is diagnosed with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis, prescribing the correct type of medicine is a case of trial and error.

29 Jan 2020

Price check on drug ads: Would revealing costs help patients control spending?

President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects.

6 Jun 2018

Researchers discover link between rheumatoid arthritis and bacteria in milk

A strain of bacteria commonly found in milk and beef may be a trigger for developing rheumatoid arthritis in people who are genetically at risk, according to a new study from the University of Central Florida.

30 Jan 2018

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.

4 Feb 2015

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.

9 Dec 2014

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor.

6 May 2014

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Simponi injection gets FDA approval to treat adults with ulcerative colitis

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.

16 May 2013

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

HealthWell Foundation introduces new lupus fund

The HealthWell Foundation, a nonprofit organization providing financial assistance to insured patients facing a variety of chronic and life-altering illnesses, announces the launch of a new fund supporting treatment for Systemic Lupus Erythematosus (SLE), the most common form of lupus.

22 Sep 2011